Bone destruction of orbital wall in idiopathic orbital inflammatory pseudotumor: does it always imply malignancy?

bone destruction idiopathic orbital inflammatory pseudotumor orbital disease

Journal

International journal of ophthalmology
ISSN: 2222-3959
Titre abrégé: Int J Ophthalmol
Pays: China
ID NLM: 101553860

Informations de publication

Date de publication:
2024
Historique:
received: 18 12 2023
accepted: 04 06 2024
medline: 19 9 2024
pubmed: 19 9 2024
entrez: 19 9 2024
Statut: epublish

Résumé

To assess the clinical presentations and outcomes of idiopathic orbital inflammatory pseudotumor (IOIP) patients with orbital wall bone destruction (OWBD) and to propose an expanded classification system that includes bone destruction. The study retrospectively reviewed clinical presentations, imaging findings, treatment modalities, and outcomes of six patients diagnosed histopathologically with IOIP and OWBD at the Beijing Tongren Hospital, Capital Medical University between October 2018 and June 2021. Over two years, 6 (10%) of 60 IOIP patients at our hospital exhibited OWBD, but this may overrepresent severe cases. The cohort consisted of three men and three women, aged 17 to 60y (mean 35.5±16.1y). Presenting symptoms included proptosis, eyelid swelling, decreased visual acuity with pain, and palpable mass. Imaging revealed multiple anatomical structures involved with the medial wall being the most common site of bone destruction. Histopathological examination showed classic type in five patients and sclerosing type in one patient. All patients underwent surgical resection followed by methylprednisolone treatment. Follow-up (mean 30.3±3.1mo) indicated three patients had no recurrence, while others had varying degrees of symptom persistence or recurrence. IOIP with bone destruction is a rare but significant subtype that mimics malignancy, leading to potential diagnostic and therapeutic challenges. Our findings suggest that complete surgical resection combined with adjunctive glucocorticoid therapy can yield favorable outcomes. However, larger-scale studies are needed to further optimize therapeutic approaches.

Identifiants

pubmed: 39296576
doi: 10.18240/ijo.2024.09.16
pii: ijo-17-09-1681
pmc: PMC11367446
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1681-1688

Informations de copyright

International Journal of Ophthalmology Press.

Déclaration de conflit d'intérêts

Conflicts of Interest: Guo QH, None; Zhang X, None; Huang AQ, None; Yang BT, None; Liu R, None; Wang N, None; Xu LY, None; Ma JM, None.

Auteurs

Qi-Han Guo (QH)

Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Xuan Zhang (X)

The Affiliated Tai'an City Central Hospital of Qingdao University, Tai'an 271000, Shandong Province, China.

An-Qi Huang (AQ)

Department of Pathology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Ben-Tao Yang (BT)

Department of Radiology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Rui Liu (R)

Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Nan Wang (N)

Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Liang-Yuan Xu (LY)

Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Jian-Min Ma (JM)

Department of Ophthalmology, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.

Classifications MeSH